search
Back to results

Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia

Primary Purpose

Fibromyalgia

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Occipital Stimulation
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibromyalgia focused on measuring Fibromyalgia, Occipital Nerve Stimulation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients able to provide informed consent to participate in the study;
  2. Patient has had chronic widespread pain for at least 3 months in all 4 body quadrants;
  3. Patient has at least 11 out of 18 tender points based on the tender points examination;
  4. Patient has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to drugs, physical therapy, acupuncture, etc.);
  5. Patient medication has remained stable for at least 4 weeks prior to baseline data collection;
  6. Psychological screening has been completed and the patient has been cleared by a psychologist as a suitable study candidate;
  7. Patient agrees not to add or increase medication throughout the randomization trial period of the study;
  8. Patient is willing to cooperate with the study requirements including compliance with the treatment regimen and completion of all office visits.

Exclusion Criteria:

  1. Patient has current evidence of any psychiatric disorder, as documented by the DSM-IV-TR criteria with psychotic characteristics, (e.g. bipolar disorder, major depressive disorder);
  2. Patient has been diagnosed with any disease mimicking the symptoms of the Fibromyalgia Syndrome (e.g. Epstein Barr, autoimmune diseases, etc.) that is not currently being treated or has not been stable for at least 6 months;
  3. Patient is currently in active menopause;
  4. Patient has been diagnosed with sleep apnea and is not currently involved in a treatment regime;
  5. Patient has a history of substance abuse or substance dependency in the past 6 months prior to baseline data collection;
  6. Patient currently participating in another clinical study;
  7. Patient with demand-type cardiac pacemakers, an infusion pump or any implantable neurostimulator device;
  8. Patient is likely to require an MRI evaluation in the future;
  9. Patient is not willing to maintain current medication regimen;
  10. Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception as determined by the investigator, or nursing (lactating) a child.

Sites / Locations

  • Universitair Ziekenhuis Antwerpen

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Sham Comparator

Active Comparator

Arm Label

Suprathreshold Stimulation

minimal stimulation

Subthreshold Stimulation

Arm Description

Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation

Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation

Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation

Outcomes

Primary Outcome Measures

Fibromyalgia Impact Questionnaire (FIQ)
The Fibromyalgia Impact Questionnaire (FIQ) is a self administered scale that was developed to measure fibromyalgia patient status, progress and outcomes. It measures the components of health that are most affected by fibromyalgia. The maximum score is 100 and a higher score indicates a greater impact of the syndrome on the person. The change in the Fibromyalgia Impact Questionnaire (FIQ) will be analyzed and reported.

Secondary Outcome Measures

Full Information

First Posted
February 14, 2011
Last Updated
January 28, 2019
Sponsor
Abbott Medical Devices
search

1. Study Identification

Unique Protocol Identification Number
NCT01298609
Brief Title
Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia
Official Title
A Randomized Controlled Pilot Study to Examine the Efficacy of Greater Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
June 2010 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is designed as a prospective, randomized, double-blind, single center study with a 6 month duration post permanent system implantation. Forty patients will be implanted. During trial stimulation, patients will be randomized into one of two study arms for two weeks. Crossover will occur at the 2 week study visit to the opposite group. After completion of these two arms, every patient will subsequently complete participation in the third study arm. After completion of the third arm, patients will be evaluated to determine if they are a positive responder responder. If so, the patient will have the option of obtaining the permanent implant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
Keywords
Fibromyalgia, Occipital Nerve Stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Suprathreshold Stimulation
Arm Type
Active Comparator
Arm Description
Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
Arm Title
minimal stimulation
Arm Type
Sham Comparator
Arm Description
Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
Arm Title
Subthreshold Stimulation
Arm Type
Active Comparator
Arm Description
Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
Intervention Type
Device
Intervention Name(s)
Occipital Stimulation
Intervention Description
Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
Primary Outcome Measure Information:
Title
Fibromyalgia Impact Questionnaire (FIQ)
Description
The Fibromyalgia Impact Questionnaire (FIQ) is a self administered scale that was developed to measure fibromyalgia patient status, progress and outcomes. It measures the components of health that are most affected by fibromyalgia. The maximum score is 100 and a higher score indicates a greater impact of the syndrome on the person. The change in the Fibromyalgia Impact Questionnaire (FIQ) will be analyzed and reported.
Time Frame
End of 6 week stimulation trial

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients able to provide informed consent to participate in the study; Patient has had chronic widespread pain for at least 3 months in all 4 body quadrants; Patient has at least 11 out of 18 tender points based on the tender points examination; Patient has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to drugs, physical therapy, acupuncture, etc.); Patient medication has remained stable for at least 4 weeks prior to baseline data collection; Psychological screening has been completed and the patient has been cleared by a psychologist as a suitable study candidate; Patient agrees not to add or increase medication throughout the randomization trial period of the study; Patient is willing to cooperate with the study requirements including compliance with the treatment regimen and completion of all office visits. Exclusion Criteria: Patient has current evidence of any psychiatric disorder, as documented by the DSM-IV-TR criteria with psychotic characteristics, (e.g. bipolar disorder, major depressive disorder); Patient has been diagnosed with any disease mimicking the symptoms of the Fibromyalgia Syndrome (e.g. Epstein Barr, autoimmune diseases, etc.) that is not currently being treated or has not been stable for at least 6 months; Patient is currently in active menopause; Patient has been diagnosed with sleep apnea and is not currently involved in a treatment regime; Patient has a history of substance abuse or substance dependency in the past 6 months prior to baseline data collection; Patient currently participating in another clinical study; Patient with demand-type cardiac pacemakers, an infusion pump or any implantable neurostimulator device; Patient is likely to require an MRI evaluation in the future; Patient is not willing to maintain current medication regimen; Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception as determined by the investigator, or nursing (lactating) a child.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roni Diaz
Organizational Affiliation
Abbott Medical Devices
Official's Role
Study Director
Facility Information:
Facility Name
Universitair Ziekenhuis Antwerpen
City
Antwerpen
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia

We'll reach out to this number within 24 hrs